Close Menu

NEW YORK – Twist Bioscience reported after the close of the market on Wednesday that revenues for its fiscal fourth quarter 2019 rose 87 percent year over year.

For the three months ended Sept. 30, 2019, the firm reported revenues of $15.7 million compared to $8.4 million in the year-ago period. It beat analysts' average revenue estimate of $14.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.